NCT02779257撤回4 期
Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 主要终点
- Hypoglycemia
研究概览
简要总结
Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older
- •Biopsy-proven (primary or metastatic lesion) metastatic neuroendocrine tumor of the gastrointestinal and pancreatic location with disease determined by CT scan or MRI
- •Patients with history of clinical syndrome symptoms (e.g. hypoglycemia)
- •Patients not controlled by treatment with currently available somatostatin analogues.
- •No evidence of significant liver disease:
- •Serum bilirubin ≤1.5 x ULN
- •INR < 1.3
- •ALT and AST ≤ 3x ULN,
- •Alkaline phosphatase ≤ 2.5 x ULN
- •Written informed consent obtained prior to treatment to be consistent with local regulatory requirements
- •Is suffering from a serious or life-threatening disease or condition
- •Does not have access to a comparable or satisfactory alternative treatment (i.e., comparable or satisfactory treatment is not available or does not exist)
- •Is not eligible for participation in any of the IMP's ongoing clinical trials or has recently completed a clinical trial that has been terminated and, after considering other options (e.g., trial extensions, amendments, etc.), the clinical team has determined that treatment is necessary and there are no other feasible alternatives for the patient
- •Meets any other relevant medical criteria for compassionate use of the investigational product
- •Is not being transferred from an ongoing clinical trial for which they are still eligible
- •There are meaningful human clinical data to support an assessment that the potential benefits to patient outweigh risks.
排除标准
- •Patients with a known hypersensitivity to somatostatin analogs or any component of the pasireotide LAR or s.c. formulations.
- •Patients with abnormal coagulation (PT or aPTT elevated by 30% above normal limits).
- •Patients on continuous anticoagulation therapy. Patients who were on anticoagulant therapy must complete a washout period of at least 10 days and have confirmed normal coagulation parameters before study inclusion.
- •Patients currently using warfarin / warfarin derivatives
- •Patients with symptomatic cholelithiasis.
- •Patients who are not biochemically euthyroid. Patients with known history of hypothyroidism are eligible if they are on adequate and stable replacement thyroid hormone therapy for at least 3 months.
- •QT-related exclusion criteria:.
- •QTcF at screening >450 msec in males, and > 460 msec in females.
- •Family history of idiopathic sudden death
- •Sustained or clinically significant cardiac arrhythmias
- •Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
- •Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
- •Family history of long QT syndrome
- •Concomitant medications known to prolong the QT interval.
- •Potassium < or = 3.5 mmol/L
- •Patients who have any severe and/or uncontrolled medical conditions :
- •Uncontrolled diabetes as defined by HbA1c > 8%
- •Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunodeficiency, including a positive HIV test result (ELISA and Western blot). An HIV test will not be required; however, previous medical history will be reviewed.
- •Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with this study treatment.
- •Life-threatening autoimmune and ischemic disorders.
- •Patients who have a history of another primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix. Patients who have had no evidence of disease from another primary cancer for 1 or more years are allowed to participate in the study.
- •Patients with history of liver disease, such as cirrhosis or chronic active hepatitis B or C
- •Presence of Hepatitis B surface antigen (HbsAg)
- •Presence of Hepatitis C antibody (anti-HCV)
- •History of, or current alcohol misuse/abuse within the past 12 months.
- •Known gallbladder or bile duct disease, acute or chronic pancreatitis
- •Patients with hypomagnesaemia (< 0.7 mmol/L)
- •Patients with a history of non-compliance to medical regimens
- •If the patient is a sexually active male he is excluded unless he agrees to use a condom during intercourse while taking pasireotide and for 3 months after stopping pasireotide medication. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid
研究组 & 干预措施
Pasireotide
Experimental
Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
干预措施: Pasireotide (Drug)
Pasireotide
Experimental
Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
干预措施: Diazoxide (Drug)
结局指标
主要结局
Hypoglycemia
时间窗: up to 12 months
number of times glucose \< 70 mg/dl with and without symptoms
次要结局
未报告次要终点
研究者
Kashif Munir
Assistant Professor of Medicine
University of Maryland, Baltimore
相似试验
Unknown
4 期
Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass SurgeryHypoglycemia, ReactiveNCT03514576Zealand University Hospital5
进行中（未招募）
1 期
Pasireotide in the treatment of low blood sugar following gastric bypass surgeryPostprandial reactive hypoglycemia in patients with prior Roux-en-Ygastric bypass surgery.MedDRA version: 20.1Level: LLTClassification code 10059038Term: Postprandial hypoglycemiaSystem Organ Class: 100000004861EUCTR2018-001067-23-DKZealand University Hospital5
已完成
不适用
Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?DiabetesCardiovascular DiseaseHypercholesterolemiaNCT00704314Medical University of Vienna20
已完成
2 期
Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor MutationsAbnormal Glucose MetabolismDiabetes MellitusInsulin ResistanceNCT02457897National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)7
终止
4 期
Use of NPH Versus Basal Bolus Insulin for Steroid Induced HyperglycemiaHyperglycemia Steroid-inducedInsulin Resistance, DiabetesNCT03511521Northwestern University3